LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.74 USD Market Closed
Market Cap: 45.8m USD

LAVA Therapeutics NV
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

LAVA Therapeutics NV
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Cash & Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Cash & Cash Equivalents
$132.4m
CAGR 3-Years
-11%
CAGR 5-Years
-3%
CAGR 10-Years
14%
ProQR Therapeutics NV
NASDAQ:PRQR
Cash & Cash Equivalents
€106.9m
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
1%
Uniqure NV
NASDAQ:QURE
Cash & Cash Equivalents
$597.1m
CAGR 3-Years
11%
CAGR 5-Years
16%
CAGR 10-Years
10%
argenx SE
XBRU:ARGX
Cash & Cash Equivalents
$1.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Cash & Cash Equivalents
$367.5m
CAGR 3-Years
24%
CAGR 5-Years
21%
CAGR 10-Years
23%
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
45.8m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.52 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

Back to Top